Professor John Zalcberg

Honorary Associate
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone 03 95328181
Fax 03 95282276

Map

Selected grants

2013

  • AGITG - Support for Cancer Clinical Trails Program; Zalcberg J; Cancer Australia/Support for Cancer Clinical Trials Program - National Cancer Cooperative Trials Groups.
  • A randomised phase III trial of preoperative chemoradiotherapy vs preoperative chemotherapy for resectable gastric cancer; Leong T, Zalcberg J, Smithers B, Boussioutas A, Haustermans K, Gebski V, Wong R, Lordick F, Swallow C, Michael M; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • Australasion Gastro-Intestinal Trials Group (AGITG); Zalcberg J; Cancer Australia/Support for Cancer Clinical Trials - Existing National Cooperative Oncology groups.

2009

  • CHALLENGE: Colon Health and Life Long Exercise Change; Courneya K, Vardy J, Meyer R, Dhillon H, Van Der Ploeg H, Zalcberg J; National Health and Medical Research Council (NHMRC)/Project: Large Scale Clinical Trial Grant.

2008

  • Preop chemoradiotherapy&postop chemo with capeciabine&oxaliplatin vs capecitabine alone in locally a; Price T, Harvey J, Tebbutt N, Hruby G, Bydder S, Simes R, Zalcberg J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2005

  • Intermediate and high risk resected gastro-intestinal stromal tumours expressing kit: RCT of adjuvant mesylate; Simes R, Zalcberg J, Mann B, Smithers B, Kotasek D, Waring P, Van Hazel G; Cancer Council New South Wales/Research Project Grants.

2003

  • A randomised trial of adjuvant chemotherapies in resectable pancreatic cancer: ESPAC-3; Padbury R, Zalcberg J, Goldstein D, Maddern G, O'Rourke J, Dhillon H; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Field, K., Zalcberg, J. (2010). Chemotherapy: Metastatic Disease. In Czito B; Willett C (Eds.), Rectal Cancer: International Perspectives on Multimodality Management, (pp. 189-222). United States: Springer Science + Business Media.

Journals

  • Carter, H., Zannino, D., Simes, R., Schofield, D., Howard, K., Zalcberg, J., Price, T., Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543. [More Information]
  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • Sjoquist, K., Zalcberg, J. (2013). Clinical Trials - Advancing National Cancer Care. Cancer Forum, 37(1), 80-87.
  • Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, R., Couture, F., Moore, M., Price, T., Siddiqui, J., et al (2013). Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 31(19), 2477-2484. [More Information]
  • Ngan, S., Burmeister, B., Fisher, R., Solomon, M., Goldstein, D., Joseph, D., Ackland, S., Schache, D., McClure, B., McLachlan, S., et al (2012). Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. Journal of Clinical Oncology, 30(31), 3827-3833. [More Information]
  • Field, K., Zalcberg, J. (2011). Biological Markers in Patients with Early-Stage Colon Cancer: Consensus and Controversies. Current Colorectal Cancer Reports, 7(3), 227-240. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]
  • De Roock, W., Jonker, D., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., Simes, R., et al (2010). Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA: The Journal of the American Medical Association, 304(16), 1812-1820. [More Information]
  • Van Glabbeke, M., Verweij, J., Blay, J., Debiec-Rychter, M., Demetri, G., Heinrich, M., Borden, E., Blanke, C., Crowley, J., Rankin, C., Zalcberg, J., Simes, R., et al (2010). Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients. Journal of Clinical Oncology, 28(7), 1247-1253. [More Information]
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.
  • Michael, M., Price, T., Ngan, S., Ganju, V., Strickland, A., Muller, A., Khamly, K., Milner, A., Dilulio, J., Matera, A., Zalcberg, J., et al (2009). A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. British Journal of Cancer, 100(1), 37-43. [More Information]
  • Au, H., Karapetis, C., O'Callaghan, C., Tu, D., Moore, M., Zalcberg, J., Kennecke, H., Shapiro, J., Koski, S., Pavlakis, N., et al (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27(11), 1822-1828. [More Information]
  • Mittman, N., Au, H., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Simes, R., Tebbutt, N., et al (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 101(17), 1182-1192. [More Information]
  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]
  • Zalcberg, J., Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2008). Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26(8), 1386-1387. [More Information]
  • Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Zalcberg, J. (2008). The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Annals of Oncology, 19(Supplement 6), vi1-vi8. [More Information]
  • Jonker, D., O’Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn, M., Price, T., Simes, R., et al (2007). Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 357(20), 2040-2048. [More Information]
  • Clarke, S., Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S. (2007). Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 6(8), 578-582. [More Information]
  • Gebski, V., Burmeister, B., Smithers, B., Foo, K., Zalcberg, J., Simes, R. (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology, 8(3), 226-234. [More Information]
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J., Clarke, S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6(2), 146-151. [More Information]
  • Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A., Blay, J., Leyvraz, S., Stul, M., Casali, P., Zalcberg, J., et al (2006). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer, 42(8), 1093-1103. [More Information]
  • Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Zalcberg, J., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2006). Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. Journal of Clinical Oncology, 24, 5194-5200. [More Information]
  • Michael, M., Thompson, M., Hicks, R., Mitchell, P., Ellis, A., Milner, A., Di Iulio, J., Scott, A., Gurtler, V., Clarke, S., Zalcberg, J., et al (2006). Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. Journal of Clinical Oncology, 24(26), 4228-4235. [More Information]
  • Millward, M., House, C., Bowtell, D., Webster, L., Olver, I., Gore, M., Copeman, M., Lynch, K., Yap, A., Wang, Y., et al (2006). The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. British Journal of Cancer, 95(7), 829-834. [More Information]
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology, 23(No 16S (June 1 Supplement)), 3581-3581.
  • Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 92(5), 832-837. [More Information]
  • Zalcberg, J., Verweij, J., Casali, P., Le Cesne, A., Reichardt, P., Blay, J., Schlemmer, M., Van Glabbeke, M., Brown, M., Judson, I., et al (2005). Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. European Journal of Cancer, 41(12), 1751-1757. [More Information]
  • Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T., Vincent, M., Schulz, J., Gonzalez Baron, M., Facchini, T. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. European Journal of Cancer, 38(4), 478-486.
  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.
  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.

2014

  • Carter, H., Zannino, D., Simes, R., Schofield, D., Howard, K., Zalcberg, J., Price, T., Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543. [More Information]

2013

  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • Sjoquist, K., Zalcberg, J. (2013). Clinical Trials - Advancing National Cancer Care. Cancer Forum, 37(1), 80-87.
  • Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, R., Couture, F., Moore, M., Price, T., Siddiqui, J., et al (2013). Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 31(19), 2477-2484. [More Information]

2012

  • Ngan, S., Burmeister, B., Fisher, R., Solomon, M., Goldstein, D., Joseph, D., Ackland, S., Schache, D., McClure, B., McLachlan, S., et al (2012). Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. Journal of Clinical Oncology, 30(31), 3827-3833. [More Information]

2011

  • Field, K., Zalcberg, J. (2011). Biological Markers in Patients with Early-Stage Colon Cancer: Consensus and Controversies. Current Colorectal Cancer Reports, 7(3), 227-240. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]

2010

  • De Roock, W., Jonker, D., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., Simes, R., et al (2010). Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA: The Journal of the American Medical Association, 304(16), 1812-1820. [More Information]
  • Field, K., Zalcberg, J. (2010). Chemotherapy: Metastatic Disease. In Czito B; Willett C (Eds.), Rectal Cancer: International Perspectives on Multimodality Management, (pp. 189-222). United States: Springer Science + Business Media.
  • Van Glabbeke, M., Verweij, J., Blay, J., Debiec-Rychter, M., Demetri, G., Heinrich, M., Borden, E., Blanke, C., Crowley, J., Rankin, C., Zalcberg, J., Simes, R., et al (2010). Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients. Journal of Clinical Oncology, 28(7), 1247-1253. [More Information]
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.

2009

  • Michael, M., Price, T., Ngan, S., Ganju, V., Strickland, A., Muller, A., Khamly, K., Milner, A., Dilulio, J., Matera, A., Zalcberg, J., et al (2009). A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. British Journal of Cancer, 100(1), 37-43. [More Information]
  • Au, H., Karapetis, C., O'Callaghan, C., Tu, D., Moore, M., Zalcberg, J., Kennecke, H., Shapiro, J., Koski, S., Pavlakis, N., et al (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27(11), 1822-1828. [More Information]
  • Mittman, N., Au, H., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Simes, R., Tebbutt, N., et al (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 101(17), 1182-1192. [More Information]

2008

  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]
  • Zalcberg, J., Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2008). Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26(8), 1386-1387. [More Information]
  • Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Zalcberg, J. (2008). The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Annals of Oncology, 19(Supplement 6), vi1-vi8. [More Information]

2007

  • Jonker, D., O’Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn, M., Price, T., Simes, R., et al (2007). Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 357(20), 2040-2048. [More Information]
  • Clarke, S., Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S. (2007). Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 6(8), 578-582. [More Information]
  • Gebski, V., Burmeister, B., Smithers, B., Foo, K., Zalcberg, J., Simes, R. (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology, 8(3), 226-234. [More Information]

2006

  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J., Clarke, S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6(2), 146-151. [More Information]
  • Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A., Blay, J., Leyvraz, S., Stul, M., Casali, P., Zalcberg, J., et al (2006). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer, 42(8), 1093-1103. [More Information]
  • Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Zalcberg, J., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2006). Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. Journal of Clinical Oncology, 24, 5194-5200. [More Information]
  • Michael, M., Thompson, M., Hicks, R., Mitchell, P., Ellis, A., Milner, A., Di Iulio, J., Scott, A., Gurtler, V., Clarke, S., Zalcberg, J., et al (2006). Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. Journal of Clinical Oncology, 24(26), 4228-4235. [More Information]
  • Millward, M., House, C., Bowtell, D., Webster, L., Olver, I., Gore, M., Copeman, M., Lynch, K., Yap, A., Wang, Y., et al (2006). The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. British Journal of Cancer, 95(7), 829-834. [More Information]

2005

  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology, 23(No 16S (June 1 Supplement)), 3581-3581.
  • Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 92(5), 832-837. [More Information]
  • Zalcberg, J., Verweij, J., Casali, P., Le Cesne, A., Reichardt, P., Blay, J., Schlemmer, M., Van Glabbeke, M., Brown, M., Judson, I., et al (2005). Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. European Journal of Cancer, 41(12), 1751-1757. [More Information]

2002

  • Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T., Vincent, M., Schulz, J., Gonzalez Baron, M., Facchini, T. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. European Journal of Cancer, 38(4), 478-486.
  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.

2000

  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.

To update your profile click here. For support on your academic profile contact .